VEGF Inhibition in Renal Cell Carcinoma Management
Author Information
Author(s): Nathan P, Chao D, Brock C, Savage P, Harries M, Gore M, Eisen T
Primary Institution: Mount Vernon Cancer Centre
Hypothesis
Can targeting VEGF improve treatment outcomes for patients with metastatic clear cell carcinoma of the kidney?
Conclusion
Targeting VEGF shows significant clinical activity in patients with metastatic clear cell carcinoma of the kidney.
Supporting Evidence
- VEGF is overexpressed in around 80% of patients with clear cell carcinoma of the kidney.
- Bevacizumab showed a significant improvement in time to progression compared to placebo.
- The overall response rate in the high-dose bevacizumab arm was 10%.
Takeaway
Doctors are finding that a special treatment that blocks a protein called VEGF can help some kidney cancer patients feel better and live longer.
Methodology
The study involved a randomized double-blind phase II trial comparing low and high doses of bevacizumab against a placebo in patients with metastatic clear cell RCC.
Limitations
The trial was not powered to detect significant survival advantages.
Participant Demographics
Patients had documented evidence of progression and most had received previous cytokine therapy.
Statistical Information
P-Value
P<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website